17
Nov
2020

Share

Winners and losers from vaccine announcements

In a year full of big moves and volatile share prices, last Tuesday saw one of the biggest disparities in the share price performance of the so called “growth vs value” stocks. The spark was the announcement from the Pfizer and BioNTech’s vaccine, which led to a significant rotation into the traditional “value” stocks, funded largely by profit taking in many growth stocks.

A closer examination of the moves also reveals significant disparity in the share price reactions in the “reopening” versus the “stay-at-home” winners, as the market de-risked the prospect of a post-COVID world. Undoubtedly some of the re-opening trades would have been accentuated by the high level of short interest in many of these stocks, while so called “stay-at-home” winners may have been impacted by the rush to lock in profits.

Here is a list of some of the moves that the market witnessed on 10 November, as well as the share price of the companies the day before and the close price as at 10 November.

 Winners and losers on the Great Rotation Day (10 November)

Screen Shot 2020-11-16 at 5.16.13 pm

Source: Bloomberg, Montgomery

Unsurprisingly, the winners on the day were the businesses most heavily impacted by COVID including travel, shopping centres, fast-fashion or retail without significant online presence and oil / energy – which had been a very notable laggard in the reopening trade momentum.

On the negative side of the ledger were generally businesses that had performed very well during COVID and throughout the year, and had seen a significant re-rate of their share prices even following the aggressive sell-off. These businesses include e-commerce, tech plays, gold miners and auto/auto parts sellers, and other beneficiaries (ventilator sellers, pizza companies).

It’s notable that many of these reversed recent price trends experienced in late October and early November had performed well in the month prior. As COVID reared its head in the Northern Hemisphere (US and Europe) movement restrictions were back and this resulted in a changing of the positive sentiment surrounding all re-opening trades experienced in September.

Investing implications

While it’s questionable that such a significant rotation would have occurred without the extremely positive “90 per cent effectiveness” headline from a reputable vaccine developer, there are two things worth noting from the moves:

  • Positioning ahead of the event – with most of the re-rating / de-rating on the “re-opening” vs “COVID winners” occurring in the first few hours, it highlights the importance of positioning ahead of the event – especially for funds that require significant liquidity to adjust their portfolio. This is despite consensus expectation that science would eventually overcome the most acute impacts of COVID-19 on society.
  • Portfolio diversification – a portfolio of “stay at home” winners would likely have outperformed materially for the past three months – however, such a portfolio would have materially underperformed on the day. Similarly, a portfolio full of “re-opening” trades may have underperformed for many months, albeit would have recouped much of the performance in a single day.

The sharp moves highlight the importance of market timing in certain situations, as well as looking ahead to potential changes to the environment.

For example, investing in retail stocks on the expectation that such strong sales growth would continue even as Australia’s COVID cases remained low and the country was re-opening held a degree of risk given the potential shift in “share of wallet” as consumers looked to spend more of their discretionary income on services. While there will be some structural winners in the retail space, it is unlikely all of these companies will grab a greater share of consumer wallets as spending patterns normalise.

On the flip side, assuming economies and societies would open entirely without regarding the risks of rolling restrictions as COVID flare-ups re-emerged would expose an investor to sharp changes in sentiment experienced in late October as previously noted. This is compounded by the potential equity damage to assets with declining values over time, most notably in the energy space given their finite reserves.

Our Funds

The Montgomery Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montgomery Global Fund

  • GLOBAL
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montaka Global Access Fund

  • GLOBAL
  • Access long/short global equity portfolio
  • From $50,000
Learn More

Montgomery Global Equities Fund (ASX:MOGL)

  • GLOBAL
  • Concentrated high conviction equities
  • No minimum investment - see your broker limits
Learn More

Montgomery Small Companies Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More
Close

Our Funds

Concentrated High Conviction Equities

Listed

Montgomery Global Equities Fund (ASX:MOGL)

Global
Available on the ASX as an Exchange Traded Managed Fund, invests in 15 to 30 quality global businesses for long-term capital growth with a target distribution yield of 4.5% per annum. Mirrors the strategy of the Montgomery Global Fund.
Unlisted From $25,000

Montgomery Global Fund

Global
Invests in 15 to 30 quality global businesses for long-term capital growth. Priced daily. Mirrors the strategy of the Montgomery Global Equities Fund (ASX:MOGL).
Unlisted from $25,000

The Montgomery Fund

Australia/NZ
Aims to provide long-term growth and income by investing in 20 to 40 high-quality Australian and New Zealand businesses trading at attractive valuations. Priced daily.
UNLISTED FROM $25,000

Montgomery Small Companies Fund

Australia/NZ
Aims to provide long-term growth by investing in 30 to 50 high quality, undervalued, Australian and NZ small and emerging companies with strong growth potential. Priced daily.
Unlisted from $1 Million

The Montgomery [Private] Fund

Australia/NZ
Seeks to deliver absolute returns from a portfolio of high-quality Australian and New Zealand businesses. Capital preservation is paramount. By invitation only.

Alternate Equity Strategies

New Fund

Montaka Global Extension Fund (ASX: MKAX)

GLOBAL
An ASX-quoted managed fund, typically, the Fund seeks to hold 15 to 30 long positions and partially offsets these with 10 to 40 short positions, operating with 130% exposure to its long portfolio and 30% exposure to its short portfolio, resulting in a net market exposure of around 100%. Features a target distribution yield of 5% per annum.
Unlisted from $50,000

Montaka Global Access Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. Priced monthly. Provides retail investors access to the Montaka Global Fund.
Unlisted from $1million

Montaka Global 130/30 Fund

Global
Provides the opportunity to benefit from both the gains of extraordinary businesses and the declines of deteriorating businesses through a global equity active extension strategy, which has the potential to significantly outperform the broader equities market over time. Seeks to generate double-digit annual average returns, net of fees. Daily priced.
Unlisted From $1 Million

Montaka Global Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. By invitation only.